MUTABILIS
Mutabilis is discovery of new therapeutic targets for the development of anti-infectives. Mutabilis is a biopharmaceutical company specialised in the discovery and development of anti-infectives. Mutabilis discovers and develops innovative anti-infectives, a novel class of drug addressing the current issues arising from resistance to antibiotics and targeting severe bacterial infections. Mutabilis’ new therapies target nosocomial infections in particular.
MUTABILIS
Industry:
Biotechnology
Founded:
2001-01-01
Address:
Paris, Ile-de-France, France
Country:
France
Website Url:
http://www.en.mutabilis.fr
Total Employee:
11+
Status:
Active
Contact:
+33 1 57 14 05 20
Total Funding:
14.24 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt WordPress Font Awesome Domain Not Resolving Apache
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Spero Therapeutics
Spero Therapeutics is developing first in class therapeutics for treatment of gram-negative infections.
Current Employees Featured
Founder
Investors List
CARB-X
CARB-X investment in Grant - Mutabilis
Repair Impact Fund
Repair Impact Fund investment in Venture Round - Mutabilis
Omnes Capital
Omnes Capital investment in Venture Round - Mutabilis
